Project Grant R01CA290017
Award Date
12/12/24
Completion Date
11/30/29
Dollars Obligated
$629K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Charleston, SC 29425, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $151,000.00 to the Medical University of South Carolina to investigate the role of polyploid cancer cells in high-grade serous ovarian carcinoma (HGSOC). The key objectives are to: (1) define the essential genes involved in the formation and lifecycle of polyploid cancer cells, and (2) determine the expression of putative biomarkers of...
The National Cancer Institute (NCI) has awarded a $621,732 project grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to The Medical University of South Carolina (MUSC). The grant will fund a 5-year hybrid effectiveness-implementation trial to evaluate a proactive identification and digital mental health intervention approach to address unmet psychosocial needs of individuals living with likely incurable cancer. The key products and services to be delivered through this...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), will fund a $334,233 research project conducted by the University of South Carolina. The project aims to examine disparities in the use of novel cancer therapies, as well as the impacts of comorbidities and multilevel factors on treatment outcomes and survival trajectories for lung and colon cancer patients, particularly among minority and rural...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $630,506 to The Johns Hopkins University to develop novel therapeutic cancer vaccines targeting human papillomavirus (HPV) for the treatment of cervical cancer. The primary goal is to employ spontaneous HPV cervicovaginal carcinoma models to characterize immune evasion mechanisms of HPV E6/E7 variants and evaluate the efficacy of a DNA vaccine against different HPV16 variants. The...
The National Cancer Institute (NCI) awarded a $2,447,812 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) federal grant program to The University of Texas MD Anderson Cancer Center. This five-year grant (Sep 2024 - Aug 2029) will fund research to maintain and enrich the MD Anderson Oropharynx (MDA-OPC) Cohort, an active, single-institution, prospective longitudinal cancer research cohort. The research will focus on three integrated projects to study and mitigate delayed...
This $146,868 federal Project Grant awarded by the National Institute of Environmental Health Sciences (NIEHS) under the Medical Library Assistance (CFDA 93.879) program aims to develop an interactive data visualization tool to inform cancer prevention and control efforts in low-income and underserved communities in South Carolina. The project will leverage the state's integrated health information database to analyze disparities in colorectal, cervical, and breast cancer outcomes among...
This Project Grant award, funded by the National Cancer Institute (CFDA 93.396 Cancer Biology Research), will support research to investigate the biological mechanisms underlying racial disparities in head and neck cancer outcomes, particularly among Black patients. The $714,062 award to the Regents of the University of California, San Francisco, with a project period from Apr 2025 to Mar 2030, has two key objectives: Develop a prognostic model using gene expression signatures to predict...
This $619,175 federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will fund a Type 1 hybrid effectiveness-implementation trial at the Medical University of South Carolina (MUSC). The trial will evaluate a novel harm reduction approach involving e-cigarette switching among oncology outpatients who smoke but refuse traditional tobacco treatment. The primary objective is to compare rates of complete switching from...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,295,508.00 to The Washington University in St. Louis for research aimed at improving the response of head and neck squamous cell carcinoma (HNSCC) to radiation therapy. The key focus is on developing and evaluating novel small molecule inhibitors of the NRF2 transcription factor, which drives resistance to radiation in over 30% of HNSCC cases. The research will leverage two potent...
This federal Project Grant award of $368,070.00 from the National Cancer Institute (NCI), under the CFDA 93.393 Cancer Cause and Prevention Research program, supports research to identify and address barriers in the cervical cancer treatment cascade among women with HIV in South Africa. The primary awardee, Trustees of Boston University, will conduct qualitative interviews and a pilot randomized controlled trial to develop a multi-level retention care intervention tailored to the unique needs of...